1044 related articles for article (PubMed ID: 26776172)
1. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
Verkhivker GM
Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
[TBL] [Abstract][Full Text] [Related]
2. The molecular basis of targeting protein kinases in cancer therapeutics.
Tsai CJ; Nussinov R
Semin Cancer Biol; 2013 Aug; 23(4):235-42. PubMed ID: 23651790
[TBL] [Abstract][Full Text] [Related]
3. Interrogating Regulatory Mechanisms in Signaling Proteins by Allosteric Inhibitors and Activators: A Dynamic View Through the Lens of Residue Interaction Networks.
Astl L; Tse A; Verkhivker GM
Adv Exp Med Biol; 2019; 1163():187-223. PubMed ID: 31707705
[TBL] [Abstract][Full Text] [Related]
4. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
5. The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.
Bailey FP; Andreev VI; Eyers PA
Methods Enzymol; 2014; 548():117-46. PubMed ID: 25399644
[TBL] [Abstract][Full Text] [Related]
6. Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics.
Verkhivker GM
Bioinformatics; 2007 Aug; 23(15):1919-26. PubMed ID: 17537753
[TBL] [Abstract][Full Text] [Related]
7. ProKinO: a unified resource for mining the cancer kinome.
McSkimming DI; Dastgheib S; Talevich E; Narayanan A; Katiyar S; Taylor SS; Kochut K; Kannan N
Hum Mutat; 2015 Feb; 36(2):175-86. PubMed ID: 25382819
[TBL] [Abstract][Full Text] [Related]
8. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
Verkhivker GM
Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
[TBL] [Abstract][Full Text] [Related]
9. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
10. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures.
Verkhivker GM
Biopolymers; 2007 Mar; 85(4):333-48. PubMed ID: 17167796
[TBL] [Abstract][Full Text] [Related]
11. Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.
Klüter S; Simard JR; Rode HB; Grütter C; Pawar V; Raaijmakers HC; Barf TA; Rabiller M; van Otterlo WA; Rauh D
Chembiochem; 2010 Dec; 11(18):2557-66. PubMed ID: 21080395
[TBL] [Abstract][Full Text] [Related]
12. Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Ruan Z; Katiyar S; Kannan N
Biochemistry; 2017 Jan; 56(1):22-32. PubMed ID: 27936599
[TBL] [Abstract][Full Text] [Related]
13. A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs.
Pal R; Berlow N
Pac Symp Biocomput; 2012; ():351-62. PubMed ID: 22174290
[TBL] [Abstract][Full Text] [Related]
14. Small-world networks of residue interactions in the Abl kinase complexes with cancer drugs: topology of allosteric communication pathways can determine drug resistance effects.
Tse A; Verkhivker GM
Mol Biosyst; 2015 Jul; 11(7):2082-95. PubMed ID: 25996455
[TBL] [Abstract][Full Text] [Related]
15. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Zhang J; Jia J; Zhu F; Ma X; Han B; Wei X; Tan C; Jiang Y; Chen Y
Mol Biosyst; 2012 Oct; 8(10):2645-56. PubMed ID: 22833077
[TBL] [Abstract][Full Text] [Related]
16. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
17. Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases.
Persky NS; Hernandez D; Do Carmo M; Brenan L; Cohen O; Kitajima S; Nayar U; Walker A; Pantel S; Lee Y; Cordova J; Sathappa M; Zhu C; Hayes TK; Ram P; Pancholi P; Mikkelsen TS; Barbie DA; Yang X; Haq R; Piccioni F; Root DE; Johannessen CM
Nat Struct Mol Biol; 2020 Jan; 27(1):92-104. PubMed ID: 31925410
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor inhibitors: a patent review (2010 - present).
Li SN; Li HQ
Expert Opin Ther Pat; 2014 Mar; 24(3):309-21. PubMed ID: 24387079
[TBL] [Abstract][Full Text] [Related]
19. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
Huang Y; Rizzo RC
Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
[TBL] [Abstract][Full Text] [Related]
20. Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.
James KA; Verkhivker GM
PLoS One; 2014; 9(11):e113488. PubMed ID: 25427151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
